WEKO3
アイテム
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study.
https://repo.qst.go.jp/records/2000469
https://repo.qst.go.jp/records/2000469dd7cb996-33c0-42a8-bd1a-75ef809f1a9e
| アイテムタイプ | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-05-23 | |||||||||||||||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||||||||||||||
| タイトル | In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. | |||||||||||||||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||||||||||||||
| 著者 |
Fukiko Hihara
× Fukiko Hihara
× Hiroki Matsumoto
× Mitsuyoshi Yoshimoto
× Takashi Masuko
× Yuichi Endo
× Chika Igarashi
× Tomoko Tachibana
× Mitsuhiro Shinada
× Ming-Rong Zhang
× Gene Kurosawa
× Aya Sugyo
× Atsushi B Tsuji
× Tatsuya Higashi
× Hiroaki Kurihara
× Makoto Ueno
× Yukie Yoshii
|
|||||||||||||||||||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||||||||||||||
| 内容記述 | Peritoneal dissemination of pancreatic cancer has a poor prognosis. We have reported that intraperitoneal radioimmunotherapy using a 64Cu-labeled antibody (64Cu-ipRIT) is a promising adjuvant therapy option to prevent this complication. To achieve personalized 64Cu-ipRIT, we developed a new in vitro tumor cell-binding assay (64Cu-TuBA) system with a panel containing nine candidate 64Cu-labeled antibodies targeting seven antigens (EGFR, HER2, HER3, TfR, EpCAM, LAT1, and CD98), which are reportedly overexpressed in patients with pancreatic cancer. We investigated the feasibility of 64Cu-TuBA to select the highest-binding antibody for individual cancer cell lines and predict the treatment response in vivo for 64Cu-ipRIT. 64Cu-TuBA was performed using six human pancreatic cancer cell lines. For three cell lines, an in vivo treatment study was performed with 64Cu-ipRIT using high-, middle-, or low-binding antibodies in each peritoneal dissemination mouse model. The high-binding antibodies significantly prolonged survival in each mouse model, while low-and middle-binding antibodies were ineffective. There was a correlation between in vitro cell binding and in vivo therapeutic efficacy. Our findings suggest that 64Cu-TuBA can be used for patient selection to enable personalized 64Cu-ipRIT. Tumor cells isolated from surgically resected tumor tissues would be suitable for analysis with the 64Cu-TuBA system in future clinical studies. | |||||||||||||||||||||||||||||||||||||
| 書誌情報 |
International journal of molecular sciences 巻 23, 号 10, p. 5087, 発行日 2022-05 |
|||||||||||||||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||||||||||||||
| 出版者 | MDPI | |||||||||||||||||||||||||||||||||||||
| ISSN | ||||||||||||||||||||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||||||||||||||||||||
| 収録物識別子 | 1422-0067 | |||||||||||||||||||||||||||||||||||||
| PubMed番号 | ||||||||||||||||||||||||||||||||||||||
| 識別子タイプ | PMID | |||||||||||||||||||||||||||||||||||||
| 関連識別子 | 35628616 | |||||||||||||||||||||||||||||||||||||
| DOI | ||||||||||||||||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||||||||||||||
| 関連識別子 | 10.3390/ijms23105807 | |||||||||||||||||||||||||||||||||||||
